We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A group of House Democrats has called on the Federal Trade Commission (FTC) to begin an investigation into potential collusion between insulin makers Eli Lilly, Novo Nordisk and Sanofi to significantly raise the price of the lifesaving drug. Read More
As Novavax gears up to file for authorizations for its two-dose COVID-19 vaccine, the U.S. drugmaker has been working to significantly expand its manufacturing capabilities in Europe and other parts of the globe and believes it can supply well over 100 million doses a month by the fall. Read More
The company has entered into multiple manufacturing pacts aimed at ramping up production, including with Emergent BioSolutions, Catalent and Merck. Read More
Johnson & Johnson (J&J) said it expects to deliver 20 million doses of its COVID-19 vaccine for the U.S. by the end of March, as officials nationwide continued to complain of severely limited supplies of the single-shot vaccine. Read More
AbbVie has filed a lawsuit alleging that Iceland-based biosimilar developer Alvotech recruited a former AbbVie employee to steal trade secrets in order to produce a biosimilar of AbbVie’s blockbuster arthritis drug Humira (adalimumab). Read More
The Russian Direct Investment Fund (RDIF) and Indian contract manufacturer Stelis Biopharma have partnered to produce 200 million doses of the Sputnik V COVID-19 vaccine. Read More
A letter to vaccination sites in the UK has cautioned that supplies of COVID-19 vaccines will be tight for about four weeks starting near the end of the month, but Pfizer has offered assurance that it is on track to meet its supply commitments on time. Read More